MISSISSAUGA, ON, Feb. 26, 2015 /CNW/ - Novo Nordisk today announced that Health Canada has approved the New Drug Submission for Saxenda® (liraglutide), the first once-daily human glucagon-like peptide ...

On December 23, 2014, the FDA approved liraglutide, under the name Saxenda, to treat obesity, after having previously approved it under the name Victoza to treat type 2 diabetes mellitus (T2DM). As ...

A new injectable drug, aimed at helping obese and seriously overweight people who have other weight-related health conditions, has proven effective in a new round of testing. The drug, called ...

Saxenda (liraglutide) is a prescription-only injectable medication in the same class as Ozempic (semaglutide). However, unlike Ozempic, Saxenda is approved by the Food and Drug Administration (FDA) ...

Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult ...

Emily McNutt is a journalist and editorial leader with extensive experience covering a range of topics from travel rewards to product reviews and financial news. With a passion for accurate reporting ...

More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major U.S ...

Saxenda (liraglutide) is prescribed for weight management. The drug comes as a liquid solution inside a prefilled pen. You inject it under your skin. Saxenda may not be safe to use while pregnant or ...

Saxenda is a brand-name subcutaneous injection that doctors often prescribe to help some people lose weight. You should keep opened Saxenda pens in the refrigerator but dispose of them after 30 days.

Saxenda is a brand-name injectable solution prescribed for long-term weight management in adults and some children. It contains the active ingredient liraglutide. Saxenda is not safe to use during ...